JP6883049B2 - アミノチアゾール化合物及びその使用 - Google Patents
アミノチアゾール化合物及びその使用 Download PDFInfo
- Publication number
- JP6883049B2 JP6883049B2 JP2018560435A JP2018560435A JP6883049B2 JP 6883049 B2 JP6883049 B2 JP 6883049B2 JP 2018560435 A JP2018560435 A JP 2018560435A JP 2018560435 A JP2018560435 A JP 2018560435A JP 6883049 B2 JP6883049 B2 JP 6883049B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- cycloalkyl
- halo
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(c(C)c1)ccc1C1=C*=*[U]1 Chemical compound Cc(c(C)c1)ccc1C1=C*=*[U]1 0.000 description 3
- TYCZVMVIYLXPSX-UHFFFAOYSA-N CCc1cc(NC(Nc(ccc(-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)c2)c2F)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(ccc(-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)c2)c2F)=O)n[o]1 TYCZVMVIYLXPSX-UHFFFAOYSA-N 0.000 description 2
- AAZWOYHDKCZELR-UHFFFAOYSA-N CC(C)(C)c1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 Chemical compound CC(C)(C)c1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 AAZWOYHDKCZELR-UHFFFAOYSA-N 0.000 description 1
- ZQIYCQCKHPAVMM-UHFFFAOYSA-N CCC1=CC(NC(Nc(cc2)ccc2-c2cnc(Nc3cc(OCCN4CCOCC4)ncn3)[s]2)=O)=[N+]1[O-] Chemical compound CCC1=CC(NC(Nc(cc2)ccc2-c2cnc(Nc3cc(OCCN4CCOCC4)ncn3)[s]2)=O)=[N+]1[O-] ZQIYCQCKHPAVMM-UHFFFAOYSA-N 0.000 description 1
- DKMMDRNAHZQBOR-UHFFFAOYSA-N CCc1cc(NC(Nc(cc2)ccc2-c2cnc(NC(N=CN3)=CC3N3CCN(CCF)CC3)[s]2)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(cc2)ccc2-c2cnc(NC(N=CN3)=CC3N3CCN(CCF)CC3)[s]2)=O)n[o]1 DKMMDRNAHZQBOR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291667P | 2016-02-05 | 2016-02-05 | |
| US62/291,667 | 2016-02-05 | ||
| PCT/US2017/015765 WO2017136315A1 (en) | 2016-02-05 | 2017-01-31 | Aminothiazole compounds and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511564A JP2019511564A (ja) | 2019-04-25 |
| JP2019511564A5 JP2019511564A5 (enExample) | 2019-11-14 |
| JP6883049B2 true JP6883049B2 (ja) | 2021-06-02 |
Family
ID=59496120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560435A Active JP6883049B2 (ja) | 2016-02-05 | 2017-01-31 | アミノチアゾール化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10047078B2 (enExample) |
| EP (1) | EP3411035B1 (enExample) |
| JP (1) | JP6883049B2 (enExample) |
| KR (1) | KR102449712B1 (enExample) |
| CN (1) | CN109069504B (enExample) |
| ES (1) | ES2909612T3 (enExample) |
| TW (1) | TWI620748B (enExample) |
| WO (1) | WO2017136315A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| CA3246244A1 (en) | 2022-03-24 | 2023-09-28 | A2A Pharmaceuticals, Inc. | CANCER COMPOSITIONS AND TREATMENT METHODS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2366932C (en) * | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| ES2257461T3 (es) * | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| EP1558609A4 (en) * | 2002-10-30 | 2008-05-28 | Merck & Co Inc | KINASE INHIBITORS |
| KR100919905B1 (ko) * | 2005-01-26 | 2009-10-06 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| AU2008355098B2 (en) | 2008-04-21 | 2012-11-15 | Gpcr Therapeutics, Inc | Heterocyclic compounds |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| ES2570177T3 (es) | 2010-08-10 | 2016-05-17 | Astellas Pharma Inc | Compuesto heterocíclico |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| CN104024246B (zh) * | 2012-03-27 | 2016-03-02 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
-
2017
- 2017-01-26 TW TW106103165A patent/TWI620748B/zh active
- 2017-01-30 US US15/419,183 patent/US10047078B2/en active Active
- 2017-01-31 EP EP17747997.9A patent/EP3411035B1/en active Active
- 2017-01-31 WO PCT/US2017/015765 patent/WO2017136315A1/en not_active Ceased
- 2017-01-31 ES ES17747997T patent/ES2909612T3/es active Active
- 2017-01-31 KR KR1020187024997A patent/KR102449712B1/ko active Active
- 2017-01-31 CN CN201780010118.4A patent/CN109069504B/zh active Active
- 2017-01-31 JP JP2018560435A patent/JP6883049B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201728583A (zh) | 2017-08-16 |
| US20170226100A1 (en) | 2017-08-10 |
| ES2909612T3 (es) | 2022-05-09 |
| KR20180132618A (ko) | 2018-12-12 |
| EP3411035B1 (en) | 2022-03-02 |
| EP3411035A1 (en) | 2018-12-12 |
| KR102449712B1 (ko) | 2022-09-30 |
| CN109069504B (zh) | 2022-06-28 |
| TWI620748B (zh) | 2018-04-11 |
| JP2019511564A (ja) | 2019-04-25 |
| US10047078B2 (en) | 2018-08-14 |
| WO2017136315A1 (en) | 2017-08-10 |
| EP3411035A4 (en) | 2019-08-14 |
| HK1258689A1 (zh) | 2019-11-15 |
| CN109069504A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI620748B (zh) | 氨基噻唑化合物及其用途 | |
| JP7550205B2 (ja) | Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩 | |
| JP7789832B2 (ja) | がんを治療するための組成物及び方法 | |
| JP2022009090A (ja) | 癌を治療するためのｋｒａｓ阻害剤の投与 | |
| TWI484960B (zh) | 嘧啶衍生物 | |
| CN117357650A (zh) | 包含sos1抑制剂的药物组合物 | |
| KR20180017013A (ko) | K-Ras 조절제 | |
| KR20070115879A (ko) | 의학 장애의 치료용 ｃｘｃｒ4 길항제 | |
| JP6979595B2 (ja) | プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 | |
| US20240245634A1 (en) | Pcna inhibitors and egfr inhibitors for cancer treatment | |
| IL298132A (en) | Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one | |
| TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
| TWI722106B (zh) | 具有抗癌活性之嘌呤化合物 | |
| JP6782710B2 (ja) | Ｒａｃ−ＧＴＰアーゼ媒介性障害を処置するための化合物 | |
| CN113727713B (zh) | 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途 | |
| CN113727981B (zh) | 激酶抑制剂及其制备、药物组合物和用途 | |
| HK1258689B (en) | Aminothiazole compounds and use thereof | |
| WO2024193509A1 (zh) | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 | |
| JP2026510535A (ja) | ホスファチジルイノシトール３－キナーゼの新規阻害剤 | |
| HK40076454A (en) | Application of fluoro-substituted 2-aminothiazole-5-aromatic carboxamide | |
| CN119841776A (zh) | 酪氨酸激酶抑制剂和其用途 | |
| HK40042521B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| WO2019143833A1 (en) | Compounds for treating rac-gtpase mediated disorder | |
| HK1233924A1 (en) | Derivatives of cephalosporin for treating cancer | |
| HK1233924B (en) | Derivatives of cephalosporin for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20181106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181106 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191001 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210421 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6883049 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |